Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19242725 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | June 2025 | February 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 18942051 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | November 2024 | January 2026 | Allow | 15 | 4 | 0 | Yes | No |
| 18755457 | ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4 | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18643312 | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19 | April 2024 | October 2024 | Allow | 6 | 2 | 1 | No | No |
| 18623246 | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19 | April 2024 | October 2024 | Allow | 7 | 2 | 0 | No | No |
| 18612854 | CD19/CD38 MULTISPECIFIC ANTIBODIES | March 2024 | September 2024 | Allow | 5 | 2 | 0 | Yes | No |
| 18611460 | ANTIBODIES WITH MUTATED HEAVY CHAIN CONSTANT REGIONS | March 2024 | October 2025 | Allow | 18 | 4 | 0 | Yes | No |
| 18590651 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | February 2024 | November 2025 | Allow | 21 | 4 | 0 | Yes | No |
| 18408414 | PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIES | January 2024 | February 2026 | Allow | 25 | 4 | 0 | Yes | No |
| 18393322 | UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLS | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18491182 | CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | October 2023 | June 2024 | Allow | 7 | 1 | 0 | No | No |
| 18464998 | COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING | September 2023 | September 2024 | Allow | 12 | 2 | 0 | No | No |
| 18238210 | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 | August 2023 | February 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18451047 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | August 2023 | January 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18361184 | SIGLEC-8 BINDING PROTEINS AND USES THEREOF | July 2023 | May 2024 | Abandon | 9 | 1 | 0 | Yes | No |
| 18340367 | ANTIBODIES BINDING SIGLEC15 AND USES THEREOF | June 2023 | January 2026 | Allow | 31 | 2 | 1 | No | No |
| 18186353 | Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof | March 2023 | September 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18164514 | HEAVY CHAIN ANTIBODIES BINDING TO PSMA | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18164386 | COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING | February 2023 | August 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18155973 | Anti-Notch2 Antibodies and Conjugates and Methods of Use | January 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18150514 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | January 2023 | July 2025 | Allow | 30 | 2 | 0 | No | No |
| 18147331 | ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF | December 2022 | September 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18145254 | ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE | December 2022 | February 2026 | Allow | 38 | 2 | 1 | Yes | No |
| 18067142 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | December 2022 | July 2025 | Allow | 31 | 1 | 0 | No | No |
| 18063477 | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | December 2022 | March 2026 | Abandon | 39 | 2 | 0 | Yes | No |
| 18058699 | ANTI-PD-L1 ANTIBODIES | November 2022 | July 2025 | Allow | 32 | 2 | 0 | No | No |
| 18055720 | ANTIBODY CONSTRUCTS | November 2022 | July 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | October 2022 | December 2024 | Allow | 25 | 4 | 0 | Yes | No |
| 17937750 | CD3 BINDING ANTIBODIES | October 2022 | July 2025 | Abandon | 33 | 1 | 0 | Yes | No |
| 17936331 | BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES | September 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17935815 | ANTIBODIES BINDING SIGLEC15 AND USES THEREOF | September 2022 | May 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 17933277 | Antibody Constructs for CDH19 and CD3 | September 2022 | June 2025 | Allow | 33 | 1 | 0 | No | No |
| 17931822 | Antibody Derivatives with Conditionally Enabled Effector Function | September 2022 | July 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17930074 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF | September 2022 | July 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17905694 | PVRIG Binding Protein And Its Medical Uses | September 2022 | January 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17822978 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | August 2022 | November 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17893998 | BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF | August 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17821143 | CD3 BINDING ANTIBODIES | August 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17819819 | ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS | August 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17885692 | METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN | August 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17798738 | ANTI-SIRPA ANTIBODIES AND METHODS OF USE | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17817599 | ANTI-THYROGLOBULIN T CELL RECEPTORS | August 2022 | January 2025 | Allow | 30 | 1 | 0 | No | No |
| 17871829 | TRISPECIFIC ANTIBODIES | July 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17813857 | Therapeutic Biologic For Treatment Of Hepatocellular Carcinoma | July 2022 | April 2025 | Allow | 33 | 2 | 0 | No | No |
| 17811828 | METHODS | July 2022 | March 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17810447 | BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY | July 2022 | September 2024 | Allow | 27 | 1 | 0 | No | No |
| 17809941 | ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES | June 2022 | February 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17809943 | ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES | June 2022 | November 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17847597 | MODIFIED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | June 2022 | July 2025 | Allow | 36 | 2 | 1 | No | No |
| 17837633 | TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE | June 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17783344 | ANTI-BCMA/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF | June 2022 | January 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17782417 | HUMANIZED CLDN18.2 ANTIBODIES | June 2022 | February 2026 | Allow | 44 | 2 | 0 | No | No |
| 17832307 | METHODS | June 2022 | February 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17827242 | CD229 Car T Cells And Methods Of Use Thereof | May 2022 | January 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17777188 | METHODS OF TREATING LUPUS NEPHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17736031 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE | May 2022 | September 2023 | Abandon | 16 | 2 | 1 | Yes | No |
| 17768701 | HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION | April 2022 | January 2026 | Allow | 45 | 2 | 0 | Yes | No |
| 17709592 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | March 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17705016 | ANTI-CEACAM5 ANTIBODIES AND USES THEREOF | March 2022 | September 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17702660 | Antibodies That Bind CD3 Epsilon | March 2022 | March 2024 | Allow | 23 | 3 | 1 | Yes | No |
| 17701764 | PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF | March 2022 | May 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17701570 | BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF | March 2022 | November 2025 | Allow | 44 | 4 | 1 | Yes | No |
| 17642130 | METHODS OF TREATING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) USING IL-17RA ANTIBODY | March 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17685216 | METHODS OF USE OF ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES | March 2022 | November 2025 | Abandon | 45 | 4 | 0 | No | No |
| 17685201 | ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES | March 2022 | November 2024 | Allow | 32 | 2 | 0 | No | No |
| 17685206 | ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIES | March 2022 | August 2025 | Allow | 41 | 4 | 0 | No | No |
| 17682367 | PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT | February 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17681737 | TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF | February 2022 | February 2026 | Abandon | 48 | 2 | 1 | No | No |
| 17652557 | MODIFIED ANTIGEN BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOF | February 2022 | January 2025 | Allow | 35 | 2 | 0 | No | No |
| 17636440 | Bispecific Antibody Targeting CD3 and CD20 and Use Thereof | February 2022 | February 2026 | Allow | 48 | 2 | 1 | No | No |
| 17648747 | ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF | January 2022 | February 2025 | Allow | 37 | 2 | 0 | No | No |
| 17582913 | ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF | January 2022 | March 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17581624 | T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS | January 2022 | November 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17576344 | Anti-Polyubiquitin Multispecific Antibodies | January 2022 | September 2024 | Allow | 32 | 1 | 0 | No | No |
| 17576800 | METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN | January 2022 | March 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17573640 | NOVEL ANTI-CD4 ANTIBODIES | January 2022 | September 2025 | Allow | 44 | 3 | 0 | No | No |
| 17573145 | COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS | January 2022 | January 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17571794 | FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region | January 2022 | May 2025 | Abandon | 40 | 2 | 1 | Yes | No |
| 17569487 | ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF | January 2022 | October 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17540044 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE | December 2021 | June 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17531199 | BIOLOGICAL MATERIALS AND USES THEREOF | November 2021 | September 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17520748 | ANTI CANCER COMBINATION THERAPY | November 2021 | October 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17517632 | ALLOGENEIC TUMOR CELL VACCINE | November 2021 | February 2026 | Abandon | 52 | 5 | 1 | Yes | No |
| 17513217 | ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS | October 2021 | March 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17512837 | Single Domain Antibodies to SARS-CoV-2 Nucleocapsid Protein | October 2021 | June 2023 | Allow | 20 | 1 | 1 | No | No |
| 17509351 | ANTI-NEUROPILIN ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | October 2021 | February 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17510160 | Anti-Abeta Antibodies | October 2021 | April 2022 | Abandon | 6 | 1 | 0 | No | No |
| 17505763 | AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | October 2021 | October 2024 | Abandon | 35 | 3 | 1 | No | No |
| 17499597 | BIOENGINEERED T CELL MEDIATED IMMUNITY, MATERIALS AND OTHER METHODS FOR MODULATING CLUSTER OF DIFFERENTIATION IV &/OR VIII | October 2021 | November 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17499127 | ANTIBODY THERAPEUTICS THAT BIND CD137 | October 2021 | August 2025 | Abandon | 46 | 3 | 0 | No | No |
| 17496240 | HETERODIMER MOLECULE BASED ON CH3 DOMAIN, AND PREPARATION METHOD AND USE THEREOF | October 2021 | December 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17601417 | HEAVY CHAIN ANTIBODIES BINDING TO PSMA | October 2021 | August 2024 | Allow | 34 | 1 | 0 | No | No |
| 17492444 | CD3 BINDING ANTIBODIES | October 2021 | June 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17477651 | ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | September 2021 | May 2023 | Allow | 20 | 3 | 1 | Yes | No |
| 17461365 | CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF | August 2021 | December 2024 | Allow | 40 | 2 | 1 | No | No |
| 17405861 | ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS | August 2021 | March 2022 | Allow | 7 | 1 | 0 | No | No |
| 17398311 | AFFINITY-ENHANCED MONMERIC STREPTAVIDIN CHIMERIC ANTIGEN RECEPTOR (CAR) | August 2021 | September 2024 | Abandon | 38 | 2 | 0 | Yes | No |
| 17387399 | COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE | July 2021 | April 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17385805 | INHIBITORY CHIMERIC ANTIGEN RECEPTORS | July 2021 | April 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17377924 | ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF | July 2021 | May 2024 | Allow | 34 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BRISTOL, LYNN ANNE.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BRISTOL, LYNN ANNE works in Art Unit 1643 and has examined 1,264 patent applications in our dataset. With an allowance rate of 57.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner BRISTOL, LYNN ANNE's allowance rate of 57.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BRISTOL, LYNN ANNE receive 2.37 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BRISTOL, LYNN ANNE is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +49.7% benefit to allowance rate for applications examined by BRISTOL, LYNN ANNE. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 50.4% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 82.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 88.5% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 83.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.1% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.1% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.